Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 05 - 05 tags : Drug save search
Amylyx Augments Case for ALS Drug Ahead of PDUFA Date
Published: 2022-05-05 (Crawled : 22:00) - biospace.com/
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
|
| O: 0.0%
H: 0.32%
C: -7.96%
drug pdufa als
Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
Published: 2022-05-05 (Crawled : 20:00) - biospace.com/
ODYY | $0.0337 354.55% 500
|
Manufacturing
|
| O: 28.45%
H: 0.0%
C: -32.76%
drug trial positive
Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines
Published: 2022-05-05 (Crawled : 19:00) - biospace.com/
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: -1.7%
H: 1.24%
C: -5.73%
tpx-4589 drug antibody gastrointestinal therapeutics license
Prime Therapeutics is acquiring Magellan Rx to advance integrated specialty drug management, accelerating efforts to lower the cost of drugs and improve health outcomes
Published: 2022-05-05 (Crawled : 18:00) - biospace.com/
CNC | $75.15 1.9% 0.0% 2.7M
|
Health Services
|
| O: -0.89%
H: 4.58%
C: 3.23%
drug health therapeutics
Global Asthma and COPD Drugs Market Report to 2030 - Opportunity Analysis and Industry Forecasts
Published: 2022-05-05 (Crawled : 18:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.18%
H: 0.46%
C: 0.46%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.98%
H: 0.0%
C: -2.72%
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.86%
H: 1.57%
C: -0.42%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.07%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.98%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.73%
H: 0.12%
C: -1.61%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.35%
H: 0.4%
C: -1.2%
report market drug
Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST
Published: 2022-05-05 (Crawled : 13:20) - biospace.com/
PCSA M | $1.58 1.28% 1.27% 19K
|
Producer Manufacturing
|
| O: 0.0%
H: 1.44%
C: 0.0%
drug conference results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.